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Abstract
Maintaining protein homeostasis is vital to cell viability, with numerous studies demonstrating a
role for proteasome inhibition occurring during the aging of a variety of tissues, and presumably
contributing to the disruption of cellular homeostasis during aging. In the present study we sought
to elucidate the differences between neurons and astrocytes in regards to basal levels of protein
synthesis, proteasome-mediated protein degradation, and sensitivity to cytoxicity following
proteasome inhibitor treatment. In these studies we demonstrate that neurons have an increased
vulnerability, as compared to astrocyte cultures, to proteasome inhibitor-induced cytotoxicity. No
significant difference was observed between these two cell types in regards to the basal rates of
protein synthesis, or basal rates of protein degradation, in the pool of short-lived proteins.
Following proteasome inhibitor treatment neuronal crude lysates were observed to undergo greater
increases in the levels of ubiquitinated and oxidized proteins, and selectively exhibited increased
levels of newly synthesized proteins accumulating within the insoluble protein pool, as compared
to astrocytes. Together, these data suggest a role for increased oxidized proteins and sequestration
of newly synthesized proteins to the insoluble protein pool, as potential mediators of the selective
neurotoxicity following proteasome inhibitor treatment. The implications for neurons exhibiting
increased sensitivity to acute proteasome inhibitor exposure, and the corresponding changes in
protein homeostasis observed following proteasome inhibition, are discussed in the context of both
aging and age-related disorders of the nervous system.
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Introduction
The degradation of proteins is necessary to maintain homeostasis and allow cells
successfully respond to cellular stressors, with an increasing number of studies
demonstrating a role for altered proteolysis contributing to cellular dysfunction in response
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to aging (1–4). In particular, a number of studies have suggested a role for impairment of the
proteasome proteolytic pathway as a mediator of cell dysfunction and pathogenesis in
response to aging and a number of age-related diseases (5–11). Despite such progress it
remains largely unknown which protein alterations are responsible for mediating the
deleterious effects of proteasome inhibition in the brain during aging and age-related
disorders of the brain.
Proteins differ significantly in regards to their rates of turnover, although most commonly
they are divided into groups of short- (minutes) and long-lived proteins (>12 hours), with the
proteasome proteolytic pathway implicated in primarily short-lived protein degradation (12–
14). Inhibition of proteasome activity has been demonstrated to activate both pro- and anti-
apoptotic pathways depending on the cell type and experimental paradigm examined (15–
20). Additionally, studies have shown that cells differ in regards to their susceptibility to cell
death following proteasome inhibition, and that some cell types may even be protected from
apoptosis by inhibition of the proteasome proteolytic pathway (21–24). The basis for these
differential effects of proteasome inhibition is almost certain to occur as the result of
differential effects on the proteome, but to date has never been elucidated for any cell type.
In this manuscript we identify for the first time that primary rat neurons are more susceptible
to the toxicity of proteasome inhibitor treatment, as compared to primary rat astrocyte
cultures. This increase in susceptibility does not appear to be due to alterations in the gross
rates of basal short lived protein synthesis or short-lived protein degradation. What is
observed for the first time is that neurons undergo increased levels of oxidized proteins as
compared to astrocyte cultures, following proteasome inhibition, with neurons also
selectively exhibiting increased accumulation of newly synthesized proteins to the insoluble
protein pool following proteasome inhibition. Taken together, these data implicate a role for
proteasome-mediated increases in oxidized proteins, and the accumulation of newly
synthesized proteins to the insoluble protein pool, as potential mediators of the selective
vulnerability of neurons to the toxicity of proteasome inhibitors.
Materials and Methods
Materials
The antibodies to β-actin (SC-47778) and ubiquitin (SC - 8017) were purchased from Santa
Cruz Biotechnology Company (Santa Cruz, CA, USA). MG132 was purchased from EMD
Chemicals (Gibbstown, NJ, USA). The BCA reagent was purchased from Thermo
Scientific, Inc. (Waltham, Illinois, USA). Oxyblot kit was purchased from Millipore
Company (Billerica, MA, USA). 35S methionine is purchased from Perkins-Elmer (Cat#
NEG009A500UC; Shelton, CT, USA). All the chemicals including Hoechts, H 33342
(bisBenzamide trihydrochloride) staining, trichloroacetic acid, Triton X-100, protease
inhibitor mix, EDTA, DNase I and cyclohexamide were purchased from Sigma-Aldrich,
Corp. (St. Louis, MO, USA). All electrophoresis and immunoblot reagents were purchased
from Bio-Rad Laboratories (Hercules, CA, USA). All cell culture supplies were obtained
from GIBCO Life Sciences (Gaithersburg, MD, USA). The proteasome substrate Suc-Leu-
Leu-Val-Tyr-AMC (for measurement of chymotrypsin-like activity) was purchased from
Bachem Inc. (Torrance, CA, USA). The BCA and micro-BCA reagents were purchased
from Thermo Scientific, Inc. (IL, USA). The black 96 well plates for reading chymotrypsin
assays were purchased from Corning Incorporated (NY, USA).
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Establishment and maintenance of primary neuron and astrocyte cultures: treatment with
MG132
Neuronal cultures were established as described previously by our laboratory (25). Briefly,
primary rat cortical neuronal cells were cultured from E18 Sprague-Dawley rats and
maintained in 5% CO2 at 37°C in MEM or Neurobasal medium containing 5% fetal bovine
serum (heat inactivated), N2 supplement, B27 supplement, and 1% antibiotic. Cells were
used in experiments between days 6–9 (Neurons) and 12–15 (Astrocytes) post plating. Rat
astrocyte cultures were established from E18 Sprague-Dawley rats as described previously
by our laboratory (22). Astrocytes were maintained in 5% CO2 at 37°C in MEM medium
containing 5% fetal bovine serum (heat inactivated), N2 supplement and 1% antibiotic
solution. All animals were utilized in accordance with IACUC approved protocols at the
Pennington Biomedical Research Center. For the analysis of protein ubiquitination and
oxidation levels following proteasome inhibition, the primary cultures of neurons and
astrocytes were treated with MG132 (0.1, 1 and 10 μM) for 15 hours and the pelleted cells
were frozen at −80°C until further use.
Analysis of cell viability
Cell survival was determined by quantification of apoptotic and necrotic nuclei using
Hoechts 344 staining as described previously (26). Briefly, Neuronal cells, treated with
MG132 (0, 0.1, 1 and 10 μM) for 15 hours, were stained with the fluorescent DNA-binding
dye Hoechts 344 at a concentration of 1μg/μl, and the percentage of viable cells were
determined by counting the number of dead cells (condensed and fragmented nuclei) using a
fluorescence microscope equipped with a 32X objective. Additional confirmation of cell
viability was determined using MTT reduction as a measure of cell viability as reported
previously (27).
Analysis of proteasome activity
Assays for chymotrypsin-like activity of proteasomes were performed using fluorogenic
Succinyl-Leu-Leu-Val-Tyr-AMC as a substrate. All assays were carried out in 250 μl of
activity assay buffer in a 96 well black assay plate with clear bottom as described previously
by our laboratory [29]. Each set came from 6 dishes of from primary cell cultures and each
set were assessed in triplicate. Following 1 hr incubation with MG132 the amount of
proteasome activity was assayed in 23 μg lysate with the 26S proteasome activity assayed in
the presence of 2 mM ATP whereas 20S proteasome activity was carried out in the presence
of 0.02% SDS (which activates 20S proteasome activity and partially inhibits the 26S
proteasome activity as described previously. The reaction mixture, following the addition of
50 μM of substrate, was incubated for 45 min at 37 °C and the fluorescence of the released
AMC product was measured in PerkinElmer plate reader at an emission wavelength of 355
nm and an excitation wavelength of 460 nm. Relative proteasome activities were represented
as percent control.
Analysis of ubiquitinated and oxidized protein levels
Protein carbonyl levels were analyzed using Oxyblot kit (Millipore) as described by the
manufacturer. Briefly, 10 μg of protein from cell lysates or 1% triton soluble and insoluble
fraction were derivatized with DNP and then the derivatized products were detected by the
Western blot analysis as described by the manufacturer. Amounts of ubiquitinated protein in
10 μg of crude lysates or 1% triton soluble and insoluble pools were detected by Western
blotting analysis using antibodies against ubiquitin.
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Analysis of protein synthesis and degradation
For the analysis of proteasome mediated degradation of proteins in primary neuronal and
astrocytes, cells were radio labeled with 35S methionine for 5 min or one hour as indicated
and the proteasome dependent degradation was studied by chase for different time points in
the presence or absence of a proteasome inhibitor,10μM MG132,. Cells, that were plated in
60mm dishes, were labeled with 35S methionine (30 μCurie) in locke’s buffer containing
154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 1mM MgCl2, 3.6 mM NaHCO3, 5mM HEPES
pH-7.2 plus 1mg/ml glucose. After labeling, the cells were chased for indicated time points
in culture medium containing 10μg/mL cyclohexamide. The cells that were pulsed and
chased in the presence of 10μM MG132 were pre incubated in the culture medium with
10μM MG132 for 1 hour, just before the labeling. After the pulse and chase, the cells were
scraped in cell lysis buffer and then the proteins were precipitated with 10% TCA by
incubating on ice for one hour. The precipitated protein was centrifuged at 10,000×g for 10
minutes and the counts of the insoluble material (pellet) were measured in Beckman
scintillation counter.
Triton X-100 fractionation of cell lysates and analysis
Triton X-100 fractionation was done as described by Qian et al., (28) with minor
modifications. We have used triton X-100 method followed by TCA precipitation to detect
the accumulation and distribution of recently synthesized proteins in triton X-100 soluble
and insoluble fractions, in the absence or presence of proteasome inhibitor, MG132. Briefly,
neuronal and astrocyte cells were labeled for 1hour in locke’s buffer with 35S methionine in
the presence or absence of MG132 as described above and chased in the cell culture medium
with 10μg/mL cyclohexamide for the indicated time points. After that the cells were
collected by scraping with the extraction buffer (150μl) containing 50mM Tris- HCl,
pH-7.4, 150mM NaCl, and 1mM EDTA, 1% triton X-100, protease inhibitor cocktail and
DNase I (buffer A). The protein lysate was incubated for 30 minutes with shaking at 4°C.
Then the triton X-100 soluble and insoluble fractions were separated by centrifugation for
20 minutes at 14,000 ×g and precipitated with 1350 μL of 11% TCA to get the final
concentration of TCA to ~10%. TCA insoluble counts in soluble and insoluble fractions of
triton X-100 were measured using scintillation counter.
The levels of ubiquitinated and oxidized proteins in triton X-100 soluble and insoluble
fractions were also analyzed by western blotting. Briefly, cells were pelleted after the
incubation in cyclohexamide for indicated time points, in the presence or absence of
MG132, exactly as described above except for labeling of cells with 35S methionine. The
pelleted cells were suspended in extraction buffer (buffer A) and incubated for 30 minutes
with shaking at 4°C and then the triton X-100 soluble and insoluble fractions were separated
by centrifugation. The protein levels in triton X-100 soluble and insoluble fractions (after
10X dilution with buffer A without Triton X-100) were estimated and equal amounts of
protein were used for the analysis of ubiquitination and oxidation levels using the western
blotting.
Protein estimation
Protein concentration of the cell lysates was estimated using BCA (Thermo Scientific)
reagent as described by the manufacturer.
Western blotting
The protein samples were analyzed by SDS-PAGE and immunoblotted with specified
antibodies as described previously by our laboratory (29).
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Results
Neuronal cells exhibit increased vulnerability to the toxicity of proteasome inhibitors
In order to begin to elucidate the relative susceptibilities of primary rat neuronal and
astrocyte cultures to the toxicity of proteasome inhibitors, we conducted studies analyzing
the severity of proteasome inhibition and induction of cell death, following treatment with
the proteasome inhibitor MG132. In these studies we observed that proteasome inhibitor
treatment resulted in a robust dose dependent impairment in 26S and 20S chymotrypsin-like
activity in both neurons and astrocytes (Fig. 1). Interestingly, the level of impairment was
nearly identical in both cell types (Fig 1). We next analyzed the levels of neuron death
following treatment with MG132 (Fig. 2), and observed that every dose of MG132 induced
significant levels of neuron death, and the highest dose utilized promoting nearly 90%
decrease in neuronal viability. In contrast, astrocytes appeared largely resistant to the
toxicity of proteasome inhibitor treatment, with only the highest doses of proteasome
inhibitors promoting approximately 10% cell death (Fig. 2). Nearly identical results were
obtained with the proteasome inhibitor MG115 (data not shown). Taken together, these data
indicate that neuronal cells are significantly more vulnerable to the acute cytotoxicity
induced by proteasome inhibitors.
Neuronal cells exhibit a significantly higher level of oxidized, but not ubiquitinated,
proteins following proteasome inhibitor treatment
Increases in ubiquitinated and oxidized proteins have been reported to occur in response to
proteasome inhibition (30–32), but the comparison between neurons and astrocytes in
regards to the severity of ubiquitinated and oxidized protein accumulation following
proteasome inhibition, has not been reported previously. In our analysis we observed that
proteasome inhibitor treatment resulted in a similar level of ubiquitinated protein
accumulation in neurons and astrocytes (Fig. 3A). Neurons exhibited a larger degree of
oxidized protein accumulation following proteasome inhibition (Fig. 3B), as compared to
astrocytes.
Short-lived protein synthesis, protein turnover, and Heat shock protein induction following
proteasome inhibitor treatment
A potential basis for the increased cytotoxicity observed in neuronal cells could be based on
differences in the relative rates of protein synthesis being higher in neuronal cells, and the
basal rate of protein degradation being slower in neuronal cells, as compared to astrocyte
cultures. In our studies we observed that neurons and astrocytes exhibited similar levels of
short-lived protein synthesis and degradation (Fig. 4). Next we analyzed the basal levels of
key heat shock proteins (Hsps) in neurons and astrocytes, as well as the Hsp levels following
treatment with MG132. In both cell types there was observed to be an increase in Hsp40 and
Hsp70 following proteasome inhibitor treatment (Fig. 5). Interestingly, the amount of Hsp40
was observed to be significantly lower in neurons as compared to astrocyte cultures (Fig 5).
The levels of Hsp90 were not significantly altered in neurons and astrocytes treated with the
proteasome inhibitor MG132 (Fig 5).
Neuronal cells exhibit selective increase in recently synthesized proteins into insoluble
protein pool following proteasome inhibition
Because the short-lived protein pool is believed to be predominantly degraded by the
proteasome, and neurons were observed to be more vulnerable to the toxicity of proteasome
inhibition, we next sought to identify if there were significant differences between neurons
and astrocytes in regards to how the short lived protein pool responds following treatment
with proteasome inhibitors. In pulse and chase studies we observed that neurons, but not
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astrocytes, underwent an increased accumulation of newly synthesized proteins within the
insoluble protein pool (Fig 6), following proteasome inhibitor treatment. No significant
alteration in the level or turnover of short lived proteins within the soluble protein pool was
observed between neurons and astrocytes (data not shown). In contrast to our findings with
crude lysates, we observed that neurons exhibited significantly higher levels of high
molecular weight ubiquitinated protein in insoluble protein pool (Fig. 7) as compared to
astrocytes. Additionally, no differences were observed in oxidized protein levels between
astrocytes and neurons in triton x-100 soluble and insoluble fractions (Fig. 8), which directly
contrasts with our findings in crude lysates. It should be noted here that neuronal cells
showed higher gross levels of oxidation as compared with astrocytes only in conditions
following prolonged incubation (15Hours) with proteasome inhibitor (Fig. 3B).
Discussion
Our studies identify for the first time that primary rat neuron cultures undergo a greater
degree of cytotoxicity following proteasome inhibitor treatment as compared to primary rat
astrocyte cultures. These data suggest that neurons may be preferentially affected by the
proteasome inhibition reported to occur in the brain during aging and age-related diseases of
the nervous system (30). In this model the negative effects of proteasome inhibition in the
brain during aging and age-related diseases, are likely mediated by the direct effect of
proteasome inhibition on neurons, as compared to indirect neurotoxicity mediated by the
effects of proteasome inhibition on non-neuronal cells. Because a primary role for the
proteasome is to degrade short-lived proteins, it is likely that the toxicity of proteasome
inhibition results from the ability of select proteins or pools of proteins to accumulate and
promote cytotoxic events in cells. However, the basis by which such alterations in the
proteome promote cytotoxicity, in particular cell type specific and/or selective cytotoxicity,
remains to be elucidated experimentally. It is also important to point out that the present
study utilizes primary cell cultures to understand the basis for neuronal and glial alterations
in the brain, and may not fully recapitulate key aspects of brain physiology. Because of this
the data need to be carefully evaluated in conjunction with additional in vivo reports to
develop a comprehensive understanding for perturbations observed in the brain.
Additionally, it is interesting to note that our study includes primary cells of mitotic
(astrocytes) and post-mitotic cells (neurons), and demonstrates that post-mitotic cells are
more sensitive to the effects of proteasome inhibitors as compared to mitotic cells, which is
consistent with previous reports in the literature on this topic. Therefore, it is important to
consider in conditions where proteasome inhibitors are used as chemotherapeutic agents that
they may promote significant and deleterious toxicity to bystander cells, and in particular
post-mitotic cells like neurons and cardiomyocytes. Such toxicity may therefore promote
constraints on the utility of proteasome inhibitors as chemotherapeutic agents, which need to
be carefully considered ad evaluated.
In this study we also demonstrate for the first time (using crude lysates) that proteasome
inhibition promotes an increase in oxidized protein levels (increased carbonyls) in neuronal
cells relative to astrocyte cultures. This data provides further support linking proteasome
inhibition to the increased levels of oxidative stress observed during aging and age-related
diseases of the brain. One primary question has been whether oxidized proteins result in
proteasome inhibition, or whether proteasome inhibition promotes the accumulation of
oxidized proteins in cells. Our data suggests that it is likely the inhibition of the proteasome
that results in the accumulation of oxidized proteins in neurons, with such increases being
relatively specific to neuron cultures as compared to astrocytes. This preferential increase in
gross oxidized protein levels in the neuronal cells likely occurs as the result of high basal
levels of oxidative stress being present in neuronal cultures relative to astrocytes, or may be
due to neuronal cells being less able to mount a sufficient heat shock protein response in
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order to effectively cope with the levels of oxidized protein following inhibition of the
proteasome. Interestingly, we have previously shown that Hsp40 levels are sufficient to
modulate sensitivity to proteasome inhibitor toxicity and oxidative stress in neural cells (10),
with neurons exhibiting a lower amount of Hsp40 as compared to astrocytes in the current
study.
An additional important and novel observation in this study arises from our identification
that following proteasome inhibition neurons exhibit a robust increase in newly synthesized
proteins within the insoluble protein pool, as compared to astrocytes. This observation may
be of fundamental importance to understanding the role of the proteasome in regulating
neuronal homeostasis and neuropathogenesis. For example, these data raise the possibility
that in neurons the proteasome plays a much more direct and significant role in rapidly
degrading newly synthesized proteins, as compared to astrocyte cultures. Additionally, these
data indicate that in the face of proteasome inhibition newly synthesized proteins themselves
are more prone to becoming insoluble in neurons as compared to astrocyte cultures. An
increase in ubiquitinated proteins within the high molecular weight fraction of insoluble
protein pool of neurons, following proteasome inhibition, suggest that the newly synthesized
proteins have been ubiquitinated so as to mark them to be removed by the ubiquitin
proteasome system. Such data while correlative, provide additional support for the ubiquitin
proteasome system in neurons being involved in the rapid bulk removal of newly
synthesized proteins, and that inhibition of the proteasome results in their rapid
accumulation in to insoluble protein pool.
Newly synthesized proteins would not be expected to have undergone all the necessary
folding and post-translational processing that are required for the generation of functional
proteins. Without such processing these proteins would be expected to be extremely
hydrophobic and prone to undergoing promiscuous interactions with other polypeptides and
proteins, which could be important in the promotion of the observed increases in protein
insolubility. Additionally, these data may be important to explaining the increase in protein
aggregation and inclusion formation that is known to occur in neurons following proteasome
inhibition. Previous studies from our laboratory and others have demonstrated that
proteasome inhibition results in rapid alterations in ribosome function and nucleolar
homeostasis in a variety of cell types including neurons (25, 33–34). Interestingly in neurons
these effects were observed to be rapid, and reversible with removal of proteasome
inhibitors. This raises the possibility that the observations in the present study may therefore
be due to proteasome inhibition promoting increased levels of translational errors,
generation of aberrant polypeptides, and/or errors in the processing proteins as they come
off of the ribosome complex. The ability of the proteasome to selectively promote these
presumably aberrant proteins in neurons as compared to astrocytes suggest that they may be
due to the proteasome being directly involved in the regulation of the ribosome via
promoting the turnover of an as yet to be identified component of the ribosome complex.
Previous studies have identified the presence of a pool of proteins which are known as
defective ribosome products (DRiPs) (28, 35), which are believed to be rapidly degraded by
the proteasome-proteolytic pathway. These defective ribosome products are believed to
occur as the result of misfolding or translational error, and are presumed to be rapidly
degraded as they are synthesized by the ribosome. Defective ribosome products, and their
degradation by the proteasome, have been studied primarily in terms of their potential role in
antigen presentation (36–38). However, the presumed increased hydrophobicity of these
polypeptides and proteins which allows for their isolation and analysis, may implicate a role
for defective ribosome products as potential modulators in the cytotoxic effects of
proteasome inhibition in multiple cell types (even non immune cells). It is interesting to note
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that the methodologies used to isolate DRiPs were employed for Figures 4 and 5 in the
present study (28), suggesting that DRiPs may be present in both neurons and astrocytes.
How could an increase in oxidized and insoluble protein result in the increase in cytotoxicity
within neurons? Firstly, previous studies have shown that even though two cell types exhibit
similar levels of proteasome inhibition following proteasome inhibitor treatment, they can
vary wildly in the amount of cytotoxicity elicited (22). There are many direct and indirect
routes by which this could occur, and further exploration of each of the many potential
pathways is likely to be important in understanding the potential role of proteasome
inhibition as a mediator of neuron dysfunction in aging and age-related diseases of the brain.
For example, current dogma suggests that oxidative stress contributes to cellular dysfunction
(39–44) and in large part via the accumulation of oxidized proteins promoting an imbalance
in multiple cellular functions due to the presumed loss of function that occurs as the result of
protein oxidation. Our data suggest that interactions between global increases in oxidized
protein levels, an insolubility of newly synthesized proteins in neurons, serves as a novel
basis by which proteasome inhibition promotes neuronal toxicity. In this model there is not
only the loss of protein function (from loss of newly synthesized proteins into an insoluble
pool), but also the genesis of insoluble proteins in neurons which are capable of promoting
neuron death via direct as well as indirect pathways.
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Figure 1. Proteasome inhibitors induce impairment of 20S and 26S proteasomes in both neurons
and astrocytes
Primary rat astrocytes and neurons analyzed for sensitivity to proteasome inhibition
following exposure to MG132. Activities of 20S and 26S were determined 1 hr following
exposure to proteasome inhibitor MG132 for 1 hour, with 20S and 26S proteasome activity
measured as described in methods. Data is representative of results from 2 separate
experiments.
Dasuri et al. Page 11
Free Radic Biol Med. Author manuscript; available in PMC 2011 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Proteasome inhibition induces more cell death in primary rat neurons as compared to
astrocytes
Cells were treated with increasing concentrations of the proteasome inhibitor MG132 and
analyzed for cell viability 24 hours post treatment. Neurons were observed to have
significantly higher levels of cell death in response to proteasome inhibitor administration
(A) as compared to astrocyte cultures (B). Results using morphological criteria as well as
nuclear condensation/fragmentation gave nearly identical results. Data are presented as the
mean and S.E.M. of results from 3 different sets of independent experiments (5 dishes per
experiment).
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Figure 3. The levels of oxidized proteins, but not ubiquitinated proteins, are increased to larger
extent in neurons as compared to astrocytes following proteasome inhibition
Rat primary cortical neurons and astrocyte cultures were analyzed for the levels of
ubiquitinated (A) and oxidized proteins (B) following treatment with proteasome inhibitors.
Cells were treated with increasing concentrations of the proteasome inhibitor 10 μM MG132
and analyzed for ubiquitinated and oxidized protein levels following proteasome inhibitor
treatment for 15 hours. Neurons were observed to have more severe increases in oxidized
proteins following proteasome inhibitor treatment. Data are representative of results from
three separate experiments.
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Figure 4. The levels of short-lived protein synthesis and degradation are similar in neurons and
astrocytes
Rat primary cortical neurons and astrocyte cultures were analyzed for protein synthesis
following a 5 minute pulse of 35S-methionine. The levels of short lived protein degradation
were analyzed in neuron and astrocyte cultures following 5 minute pulse of 35S-methionine
and corresponding increasing lengths of chase period. Results indicate that neurons and
astrocytes have similar levels of short lived protein synthesis (A) and short lived protein
degradation (B). Data are presented as the mean and S.E.M. of results from 3 independent
set of experiments with 4 dishes for each time point in an experiment.
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Figure 5. Heat shock proteins in neurons and astrocytes following proteasome inhibition
Lysates from rat primary cortical neurons and astrocyte cultures were analyzed by Western
blotting for the levels of heat shock protein induction following proteasome inhibition for 15
hours. Antibodies against the Hsp40, Hsp70 or Hsp90 were used in the analysis. Beta actin
was used to show the equal loading of protein lysates. Data represent the 3 independent set
of experiments done under similar conditions.
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Figure 6. Proteasome inhibition resulted in increased accumulation of recently synthesized
proteins in Triton x-100 insoluble fraction of neurons, as compared with astrocytes
Rat primary neurons and astrocytes were pulsed for one hour with 35S-methionine and
chased for indicated time points in the presence or absence of proteasome inhibitor, MG132.
Whole cell lysates were separated in to triton X-100 soluble and insoluble fractions and
TCA insoluble radioactivity of these fractions was measured as described in methods.
Proteasome inhibition resulted in the accumulation of higher levels of recently synthesized
short lived proteins in triton X-100 insoluble fractions of primary neurons (A) when
compared with the astrocytes (B). Data are presented as the mean and S.E.M. of results from
3 different sets of independent experiments.
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Figure 7. Proteasome inhibition resulted in increased accumulation of recently synthesized
proteins, that are ubiquitinated, in triton x-100 insoluble pool of neurons as compared with
astrocytes
Rat primary Neurons and astrocytes were collected after treatment with cyclohexamide for
indicated time points in the presence or absence of proteasome inhibitor, MG132, as
described in methods. Whole cell lysates were fractionated by Triton X-100 and the amounts
of ubiquitinated proteins in Triton X-100 soluble and insoluble fractions were analyzed
using western blot analysis. Results indicate the increased accumulation of recently
synthesized proteins, that are higher molecular weight ubiquitinated proteins, in triton x-100
insoluble pool of neurons (A), as compared with astrocytes (B), following proteasome
inhibition.
Dasuri et al. Page 17
Free Radic Biol Med. Author manuscript; available in PMC 2011 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 8. Primary Neuron and astrocytes showed no differences in the levels of oxidized proteins
in triton x-100 soluble and insoluble fractions following proteasome inhibition
Rat primary neurons and astrocytes were collected after treatment with cyclohexamide for
indicated time points in the presence or absence of proteasome inhibitor, MG132, as
described in methods. Whole cell lysates were fractionated by triton X-100 and the amounts
of oxidized proteins in triton X-100 soluble and insoluble fractions were analyzed as
described in methods. Results did not show differences in the levels of oxidized proteins in
triton x-100 insoluble and soluble fractions between neurons (A) and astrocytes (B)
following proteasome inhibition.
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